01—Abstract
Summary
Summary of the 10-K filed February 20, 2024. Cited figures are marked; the original filing is the authoritative source.
Centene Corporation's (CNC) 2023 10-K filing reveals a year of significant strategic repositioning, marked by substantial divestitures and a focus on profitable growth through its core government-sponsored healthcare programs.
The company reported total revenues of $154.0 billiona, a 7% increase year-over-year, driven primarily by strong performance in its Medicaid and Commercial segments, particularly the Health Insurance Marketplace (Ambetter Health). Despite a 2% increase in overall membership to 27.5 million, the company experienced a decline in its Medicare membership. Financially, Centene demonstrated improved profitability, with diluted EPS of $4.95, a significant increase from $2.07 in the prior year, and adjusted diluted EPS of $6.68, up over 15%.
This improvement was achieved despite $529 millionb in impairment charges, largely related to divestitures and real estate optimization. The company also generated strong operating cash flows of $8.1 billion, highlighting operational efficiency.
Key strategic moves in 2023 included the completion of several divestitures (Operose Health, Circle Health) as part of its Value Creation Plan, alongside $1.6 billionc in share repurchases. Looking ahead, Centene is focused on margin expansion, leveraging its scale, and navigating evolving regulatory landscapes, particularly within the Medicare and Medicaid programs.
02—Key points
Key Highlights
- Total revenues grew 7% year-over-year to $154.0 billion, driven by strong performance in Medicaid and the Health Insurance Marketplace.
- Diluted Earnings Per Share (EPS) surged to $4.95, a substantial increase from $2.07 in the prior year, with adjusted diluted EPS growing over 15% to $6.68.
- Operating cash flow remained robust at $8.1 billion, demonstrating strong cash generation capabilities.
- Centene completed several strategic divestitures in 2023, including Operose Health and Circle Health, as part of its Value Creation Plan aimed at streamlining operations and focusing on core business areas.
- Share repurchases totaled $1.6 billion in 2023, reflecting the company's commitment to returning capital to shareholders.
- Medicaid segment revenue increased 8%, while the Commercial segment saw a significant 43% revenue increase, largely due to growth in the Health Insurance Marketplace (Ambetter Health).
- The company established a $250 million premium deficiency reserve for its 2024 Medicare Advantage business, reflecting anticipated revenue impacts from star rating changes and CMS pricing adjustments.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2023, Centene Corp kept $0.02.
- Revenue$154.00B100.0%
- Cost of revenue−$136.36B88.5%
- Gross profit$17.64B11.5%
- Operating costs−$14.71B9.6%
- Operating income$2.93B1.9%
- Interest, other & tax−$228.0M0.1%
- Net income$2.70B1.8%
Where FY2023 revenue went
$154.00B- Other operating costs: $134.94B, 88% of revenue
- Net income: $2.70B, 1.8% of revenue
- Cost of revenue: $3.56B, 2.3% of revenue
- SG&A: $12.56B, 8.2% of revenue
Kept 1.8% as net incomeNet income $2.70B · 1.8%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 20, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $154.00B$144.55B | +6.5% |
| Cost of Revenue | $3.56B$7.03B | −49.3% |
| Gross Profit | $17.64B$16.92B | +4.2% |
| SG&A Expenses | $12.56B$11.59B | +8.4% |
| Operating Expenses | $151.07B$143.23B | +5.5% |
| Operating Income | $2.93B$1.32B | +122.3% |
| Interest Expense | $725.00M$665.00M | +9.0% |
| Net Income | $2.70B$1.20B | +124.8% |
| EPS (Basic) | $4.97$2.09 | +137.8% |
| EPS (Diluted) | $4.95$2.07 | +139.1% |
| Shares Outstanding (Basic) | 543.32M575.19M | −5.5% |
| Shares Outstanding (Diluted) | 545.70M582.04M | −6.2% |
05—Questions
Frequently Asked Questions
What were Centene's key financial performance indicators for 2023?
Centene reported total revenues of $154.0 billion, a 7% increase year-over-year. Diluted EPS was $4.95, up from $2.07 in 2022, and adjusted diluted EPS was $6.68, an increase of over 15%. Operating cash flow was strong at $8.1 billion.
What were Centene's significant strategic actions in 2023?
Centene completed several strategic divestitures, including Operose Health and Circle Health, as part of its Value Creation Plan. The company also repurchased $1.6 billion of its common stock and focused on modernizing its operating model, standardizing its pharmacy operations, and launching a next-generation clinical population health platform.
How did Centene's different business segments perform in 2023?
The Medicaid segment saw an 8% increase in revenue, while the Commercial segment experienced a substantial 43% revenue increase, primarily driven by growth in the Health Insurance Marketplace (Ambetter Health). Medicare segment revenues decreased slightly by 1%, impacted by lower enrollment and a premium deficiency reserve.
What are the primary risks and uncertainties facing Centene, as highlighted in the filing?
Key risks include the ability to accurately estimate and manage medical costs, regulatory changes and government funding for its core Medicaid and Medicare programs, competition, cybersecurity threats, and the potential for disruptions in operations due to vendor performance or system failures. The company also highlighted risks related to the Inflation Reduction Act's impact on Medicare Part D and the ongoing need to manage Medicare Star ratings.
06—Continue